Latest Capital Financing News

Western Gold Resources has sharply expanded the proposed Gold Duke mine, lifting its production target by 62% and forecasting A$72.9 million in operating surplus. The preliminary study is stronger on paper, but still depends on funding and the restart of toll treatment at Wiluna.

Nuchev Limited grew revenue by 12% in FY26, driven by domestic expansion, yet saw margins contract and adjusted EBITDA losses deepen to A$4.6 million. The company’s FY27 focus shifts to margin improvement, operating leverage, and cash conversion.

Aguia Resources has rapidly converted its Pampafós phosphate fertiliser project into commercial sales, securing AUD 600,000 in revenue within 14 days, anchored by a 2,000-tonne contract with a leading Brazilian agricultural cooperative.

International Graphite Ltd (ASX:IG6) has partnered with Alkeemia S.p.A. to establish a graphite processing facility in Italy, aiming for first production in the second half of 2027 and a final investment decision by Q3 2026.

Minbos Resources has secured a US$5.48 million debt facility from Banco de Fomento Angola, complementing a prior US$16 million loan from South Africa’s IDC, ensuring full funding to complete construction of its Cabinda Phosphate Fertilizer Plant.

Earlypay Limited has withdrawn its FY26 earnings guidance due to increased costs and credit losses, signaling a cautious outlook despite solid growth in new business.

McPherson’s Limited has secured a new $16.2 million debt facility with HSBC, significantly downsizing from its previous $52.5 million arrangement as part of its ongoing business transformation.

Earlypay Limited has extended its on-market share buy-back program for another 12 months, allowing the company to repurchase up to 10% of its ordinary shares without shareholder approval.

Antilles Gold advances its Cuban mining ambitions with a binding EPC contract signed and construction slated to begin early next year at the Nueva Sabana copper-gold project.

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.

Earlypay Limited reported a 24% rise in underlying net profit after tax for FY25, driven by robust growth in equipment finance and improved credit performance, while declaring a fully franked dividend and forecasting further earnings growth in FY26.

Zelira Therapeutics reports promising diabetic neuropathy study results with ZLT-L-007 surpassing Lyrica, while converting $3.25 million in notes to equity to bolster HOPE® 1 clinical development.